Favezelimab-Pembrolizumab for treating relapsed or refractory classical Hodgkin Lymphoma after 2 or more therapies

Co-formulated favezelimab-pembrolizumab is in clinical development for patients with relapsed or
refractory classical Hodgkin Lymphoma (cHL) who have exhausted all available treatment options and
whose disease has progressed on treatment with an anti-PD-(L)1 monoclonal antibody. Hodgkin
lymphoma is an uncommon cancer that develops in the lymphatic system, which is a network of vessels
and glands spread throughout your body. cHL is the most common type of Hodgkin lymphoma. The
relapsed form of disease means the cancer has come back, while refractory disease means the cancer has
stopped responding to treatment. Some lymphoma patients progress after chemotherapy and
immunotherapy, and as such have fewer available treatment options. Therefore, there is an unmet need
for effective therapies for patients with resistant cHL.